Indonesia, Philippines, Vietnam and Brazil
Indonesia: Health Supplements 2025 Agenda BPOM (the Indonesian Food and Drug Agency) has published its Regulatory Roadmap for 2025, identifying Health Supplements as a key focus area. Some of the key areas addressed are: • Labelling: companies are required to disclose the source of their […]
Brazil: ANVISA Novel Foods Tool | New Upper Limit for Creatine
ANVISA Free Tool for Novel Foods ANVISA has developed a tool to determine whether a specific ingredient is classified as a Novel Food or New Ingredient. This tool, which is available free of charge, aims to help companies understand whether their ingredients are considered a Novel Food or […]
Brazil: Public Consultation on Ingredient Specs | Ban on Food Supplements with ora-pro-nobis | Safe Use of Erythrosine | Update on Plastic Packaging
Brazil and New Normative of Specifications for Ingredients From May 2nd until June 16th, a public consultation is being held regarding ANVISA’s proposal for a new norm that outlines the specifications for ingredients. This proposal is structured into 4 annexes: • Annex 1 – New Ingredients with […]
Brazil: New normative of specifications for ingredients (new ingredients and novel foods)
Last week, Brazil approved a new Normative Instruction that will regulate petitions in the food sector based on approvals already granted by Equivalent Authorities from Foreign Countries (known as Autoridades Reguladores Estrangeiras Equivalentes – AREEs – in Portuguese). This new norm is a significant step toward streamlining Brazil’s approval system, as it will allow petitions submitted to ANVISA to reference […]
Brazil: Petitions submitted to ANVISA can refer to pre-approvals from FDA, EFSA and Codex
Last week, Brazil approved a new Normative Instruction that will regulate petitions in the food sector based on approvals already granted by Equivalent Authorities from Foreign Countries (known as Autoridades Reguladores Estrangeiras Equivalentes – AREEs – in Portuguese). This new norm is a significant step toward streamlining Brazil’s approval system, as it will allow petitions submitted to ANVISA to reference […]
